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Very early alloantigen-
independent trafficking of 
lymphocytes during ischemic 
acute kidney injury
MT Gandolfo1 and H Rabb2
Lymphocytes play an important role during ischemia–reperfusion 
injury (IRI). Lai et al. have demonstrated, for the first time, an increase 
in kidney lymphocytes 1 hour after IRI, a newly identified kidney 
lymphocyte reservoir, and have confirmed the pathogenic role of 
lymphocytes by manipulating the sphingosine-1-phosphate (SIP)– 
sphingosine-1-phosphate type 1 (S1P1) receptor pathway.
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Ischemic acute kidney injury (AKI) in 
native kidneys is associated with a high 
mortality rate and in allografts is the 
main cause of delayed graft function, 
increases rejection rates, and shortens 
long-term graft  survival. Th e pathogene-
sis of ischemic AKI, experimentally called 
kidney ischemia–reperfusion injury (IRI), 
involves a complex interplay among micro-
vascular, tubular epithelial, and humoral 
mediators. Infl ammation plays a major 
role in the induction and amplifi cation of 
IRI, with cellular as well as soluble factors 
participating. An unexpected pathophysi-
ologic role for T cells during the initiation 
phase of kidney IRI has recently been 
elucidated on the basis of work from a 
number of diff erent groups1–5 (Figure 1). 
T cells also play an important role in liver, 
lung, intestinal, and brain IRI (reviewed 
by Ascon et al.5). One of the main reasons 
why this important fi nding was previously 
overlooked is that few T cells are found 
during AKI in human kidney biopsy sam-
ples, which are usually from the cortex. 
However, classic studies had identified 
mononuclear leukocytes in the vasa recta 
in human AKI.6 Given that few T cells 
were described in kidney during experi-
mental AKI at the time of overt tubular 
injury and elevation in serum creatinine, 
a ‘hit and run’ model was proposed: T cells 
would infiltrate very early into kidney, 
instigate and incite deleterious pathways, 
and then disappear at later times when 
kidney tissue was studied at 24 hours.7 
To test this hypothesis and improve on 
current approaches to functionally char-
acterize kidney-infi ltrating leukocytes, a 
lymphocyte isolation technique followed 
by flow cytometry analysis was devel-
oped to identify and characterize small 
numbers of kidney lymphocytes.5 This 
isolation technique, in combination with 
immunohistochemistry, demonstrated 
that T cells infi ltrate the kidney within 
3 hours aft er ischemia and then are largely 
gone by 24 hours when serum creatinine 
is elevated and tubules grossly damaged. 
Th e infi ltrating T cells (including natural 
killer T cells) produce large amounts of 
interferon-γ and tumor necrosis factor-α, 
which can activate other leukocytes as well 
as directly modify intrarenal cells.
In order to translate experimental data 
on lymphocytes in kidney IRI to human 
benefi t, therapeutic approaches to miti-
gate early lymphocyte function in IRI have 
been attempted. Lymphocyte depletion 
techniques have been successfully per-
formed in a small study in humans involv-
ing deceased-donor kidney transplants.8 
Alternatively, in experimental IRI, agents 
that prevent infi ltration into the kidney by 
interfering with lymphocyte recirculation, 
such as the sphingosine-1-phosphate type 
1 (S1P1) receptor agonist FTY720, have 
been successfully used.9 S1P1 receptor is 
present on endothelial cells and immune 
cells (T and B lymphocytes, macro-
phages, and dendritic cells) and appears 
to be crucial for the lymphocytes’ egress 
from secondary lymphoid organs and 
for the endothelial barrier functions in 
these organs. Th e nonselective agonist 
FTY720 has demonstrated limited addi-
tional improvement in efficacy for the 
prevention of renal allograft  rejection in 
two large phase III studies. Th ese results 
in combination with observed side eff ects 
including bradycardia and macular edema 
have limited further development of this 
nonselective agent in renal transplanta-
tion.10 Because the side eff ects seem to be 
mediated by S1P3 receptor activation, the 
development of selective S1P1 receptor 
agonists, available for clinical purposes, 
is being investigated in several centers.
Lai et al.11 (this issue) directly tested 
the ‘hit and run’ hypothesis mentioned 
above by carefully examining the kinet-
ics and location of T cells in the kidney 
with immunohistochemistry aft er IRI. 
Th ey found lymphocytes in the kidney 
within 1 hour of IRI, earlier than others 
had demonstrated, and then confi rmed 
the finding of other studies that lym-
phocytes are largely absent by 24 hours 
aft er IRI. Surprisingly, the early increase 
in lymphocytes was in the tissue compart-
ment and not in the microvasculature as 
previously demonstrated.3 Remarkably, 
Lai et al.11 also observed that the lym-
phocytes were coming from a renal res-
ervoir (the periarterial space between the 
renal cortex and the lining of pelvic for-
nix), where they form aggregates in nor-
mal mice. Early during the reperfusion 
period, whereas CD4+ T cells increased in 
the damaged interstitium of the cortical–
medullary junction, they were reduced in 
the blood and in the periarterial area. Th e 
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authors implicated the periarterial space 
between the cortex and pelvic fornix as 
part of the renal lymphatic system. Th eir 
assumption derived in part from studies 
conducted in animal models that demon-
strated the presence of lymphatic vessels 
in the connective tissue that surrounds the 
interlobar and arcuate arteries and veins. 
An analysis of the human renal lymphatic 
system using specifi c immunostaining 
with anti-D2-40 antibody showed that 
lymphatics are abundant in the intersti-
tium around the major intrarenal vessels 
but uncommon around the glomeruli and 
between the tubules in the cortex.12 Lai et 
al.’s hypothesis of a novel kidney ‘niche’11 
has similarities to the recent fi nding that 
the usually overlooked renal papilla is an 
important source of kidney stem cells that 
aid in tissue repair.13
In the second part of their work, Lai 
et al.11 used the S1P1 receptor-selective 
agonist SEW2871 to prevent the early 
lymphocyte infi ltration into kidney and 
closed the loop by demonstrating a tissue 
and functional protection from IRI by this 
maneuver. Th ey also demonstrated that 
chemokine mRNA levels were not infl u-
enced by SEW2871; thus changes in the 
chemotactic gradient to lymphocytes are 
unlikely to explain the reduction in lym-
phocyte migration aft er IRI that resulted 
from SEW2871. Overall, the study by Lai 
et al.11 is elegant with simple techniques, 
demonstrating a newly recognized local 
lymphocyte infl ammatory circuit in kid-
ney. However, these results need to be 
confi rmed with other techniques besides 
immunohistochemistry to really home 
in on the location of these cells and the 
mechanisms of migration. For example, 
to assess whether the early-infi ltrating T 
cells were truly all extravascular, use of 
specifi c antibodies to label endothelial 
cells in addition to T cells, followed by 
confocal microscopy or electron micros-
copy, would be more convincing.
Many questions remain unanswered 
in this area of investigation: Do the lym-
phocytes that modulate the renal response 
to IRI all have to migrate from outside the 
kidney, or does the kidney itself have a 
resident lymphocyte population that can 
be activated, as recently demonstrated 
(D Ascon et al., Am Soc Nephrol Meetings 
2006, abstract issue, 799a)? What are the 
mechanisms for such a rapid migration 
of lymphocytes in the absence of alloan-
tigens or identifi ed self-antigens? Does the 
T-cell receptor on lymphocytes, required 
in classic immune models, participate in 
IRI — a controversial topic recently put to 
rest by convincing data that T-cell recep-
tor indeed is a key mediator of kidney 
IRI (K Hochegger et al., Am Soc Neph-
rology 2006, abstract issue, 709a)? How 
do lymphocytes interact with other cells 
and soluble factors in IRI given that so 
few cells can infl uence signifi cant kidney 
functional and structural changes? Can 
lymphocytes, depending on the exact type 
and kinetics, also play a role in protecting 
from ischemia and also infl uence healing? 
Given that many of the experimental stud-
ies have occurred in rodents, how relevant 
are these fi ndings to human AKI? Are the 
S1P receptors and other molecular targets 
working purely through lymphocytes or 
also through other pathways? It will be 
important to investigate these and related 
questions given the current availability of 
lymphocyte modulating agents and the 
urgency for the development of eff ective 
therapies for human AKI.
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Figure 1 | Mechanisms of lymphocyte action during kidney ischemia–reperfusion injury. 
Kidney ischemia–reperfusion injury (IRI) is characterized by endothelial dysfunction, sublethal 
injury to renal tubule epithelial cells, and an increased production of chemokines, cytokines, and 
oxygen free radicals that amplifies cell damage. Exposure of antigens in the kidney after IRI activates 
antigen-presenting cells (APCs) that migrate to the draining lymph nodes and present the antigen–
MHC II complex to T lymphocytes using specific T-cell receptor (TCR) recognition. Activation of 
lymphocytes requires costimulatory molecules. Activated T lymphocytes infiltrate into kidney from 
blood, recruited by chemokines into the damaged kidney. Lymphocytes, neutrophils, macrophages, 
and platelets physically contribute to microvascular sludging and ‘no-flow.’ Microvascular adhesion, 
signaling, and transmigration into parenchyma are mediated by adhesion molecules, which further 
amplify inflammation and cytotoxic injury. T lymphocytes, both infiltrating and resident, can also 
be activated directly in situ by reactive oxygen species and chemokines or as a result of direct 
contact with tubular cells. CD40, present on tubular cells, interacting with CD40 ligand (CD40L) on 
T lymphocytes, leads to the production of chemokines by the epithelial cells with activation and 
further recruitment of leukocytes. Lymphocyte function–associated antigen-1 (LFA-1); intercellular 
adhesion molecule-1 (ICAM-1);  MHC, major histocompatibility complex.
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Adiponectin and renal 
disease progression: Another 
epidemiologic conundrum?
C Zoccali1 and F Mallamaci1
In an analysis based on the Mild to Moderate Kidney Disease (MMKD) 
study, adiponectin, a pleiotropic, insulin-sensitizing, anti-inflammatory 
and vasculo-protective cytokine, was directly related to renal disease 
progression. The precise definition of this apparently paradoxical 
association now requires that the research focus be moved from the 
study database to the experimental laboratory.
Kidney International (2007) 71, 1195–1197. doi:10.1038/sj.ki.5002319
An interesting observational study by 
Kollerits et al.1 (this issue) shows for the 
first time that adiponectin (ADPN) is 
a direct predictor of renal disease pro-
gression in male patients. As ADPN is 
a pleiotropic, insulin-sensitizing, anti-
inflammatory and vasculo-protective 
cytokine, these results are apparently 
counterintuitive with respect to biological 
eff ects of this peptide. Th is study off ers a 
stimulating starting point for discussing 
the use of observational studies in the 
complex process of causality assessment 
and for focusing on the fundamental 
importance of the clinical context wherein 
a given risk factor is being tested.
Observational studies and etiologic 
research
The problem of causality is central to 
clinical medicine. Inferring the cause 
of a given disease is a creative process 
based on conjectures and refutations that 
requires a variety of scientifi c verifi cations, 
including epidemiologic and experimen-
tal studies.2 Th e concept of risk factor for 
the study of multifactorial diseases such 
as hypertension, atherosclerosis, and 
chronic kidney disease (CKD) was devel-
oped about 50 years ago by investigators 
of the Framingham study. Th is concept 
is now used both to explore the causes of 
diseases (etiologic research) and to esti-
mate the probability of adverse outcomes 
(prognostic research). Although based on 
common statistical techniques, these two 
types of research are conceptually much 
diff erent. When we test the association of a 
putative risk factor — for example, ADPN 
— as a causal risk factor for renal disease 
progression (etiologic research), we ought 
to establish whether this association is 
independent of other risk factors; that is, 
we ought to exclude that the association 
is spurious because of the link of ADPN 
with other well-known risk factors. To 
this end, the clinical investigator and the 
biostatistician construct multivariate mod-
els that allow control for confounding by 
other risk factors. Th is approach is similar 
to that applied by a scientist who tests the 
eff ect of ADPN in experimental animals. 
In such an experiment, animals randomly 
receive either ADPN or an inert substance 
(control group). If properly performed, 
an experiment of this kind can isolate the 
eff ect of ADPN from other factors, because 
randomization equalizes both known and 
unknown risk factors, excluding ADPN, 
among the experimental animals; that is, 
randomization produces groups that, on 
average, have very similar blood pres-
sure, cholesterol, renal function, and so 
on. When all risk factors are similar, the 
outcome is determined only by the experi-
mental maneuver, that is, by exposure or 
lack of exposure to ADPN. Likewise, in 
prospective cohort studies, multivari-
ate analysis makes it possible to set all 
known risk factors but the factor being 
tested at the average value and to adjust 
the outcome accordingly. It is important to 
emphasize that, however accurate they can 
be, observational studies have the obvious, 
inherent limitation that they cannot con-
trol for unknown risk factors, a problem 
that can be resolved only with randomized 
experiments. It is worth mentioning that, 
whereas control for confounding is funda-
mental in etiologic research, confounders 
are absolutely not a problem in prognostic 
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